Edited by: Hee Jeong Kim, Asan Medical Center, South Korea
Reviewed by: Qiang Liu, Chinese Academy of Medical Sciences and Peking Union Medical College, China; Alfredo Santinelli, Azienda Ospedaliera “Ospedali Riuniti Marche Nord”, Italy
*Correspondence: Kun Wang,
†These authors have contributed equally to this work
This article was submitted to Women's Cancer, a section of the journal Frontiers in Oncology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
The influence of surgical approaches [including mastectomy, breast-conserving therapy (BCT) and post-mastectomy breast reconstruction (PMBR) on prognosis of young women (<40 years old) with operable breast cancer has not been determined yet, and this might vary in patients with different marital statuses. Therefore, we aimed to investigate the effect of surgery on survival outcomes for young women with operable breast cancer in different marital statuses.
We used the Surveillance, Epidemiology, and End Results (SEER) database to identify young women with operable breast cancer between 2004 and 2016, who underwent mastectomy, BCT or PMBR. We assessed overall survival (OS) and breast cancer-specific survival (BCSS) using the Kaplan–Meier method and hazard ratios using multivariate Cox proportional hazard regression.
Compared to mastectomy, both of BCT and PMBR conferred better OS (BCT: HR = 0.79, 95%CI: 0.69–0.90, p <0.001; PMBR: HR = 0.70, 95%CI: 0.63–0.78, p <0.001) and BCSS (BCT: HR = 0.79, 95%CI: 0.69–0.91, p = 0.001; PMBR: HR = 0.73, 95%CI: 0.65–0.81, p <0.001), but there was no significant difference of survival between BCT and PMBR group. The survival benefit of BCT compared to mastectomy remained significant in unmarried young women (OS: HR = 0.68, 95%CI: 0.55–0.83, p <0.001; BCSS: HR = 0.69, 95%CI: 0.56–0.86, p = 0.001) but not in the married (OS: HR = 0.89, 95%CI: 0.75–1.05, p = 0.177; BCSS: HR = 0.89, 95%CI: 0.75–1.05, p = 0.161), while no matter married or not, PMBR group had better OS and BCSS than mastectomy group but not BCT group.
Both of BCT and PMBR had improved survival compared to mastectomy for young women with operable breast cancer. The survival benefit of BCT compared to mastectomy remained significant in unmarried patients but not in married patients.
香京julia种子在线播放
Nowadays, treatment strategies for breast cancer have been improved largely, including surgery, radiation, chemotherapy, endocrine therapy, target therapy and immune therapy (
For breast cancer in young women, which are defined as women under the age of 40 at breast cancer diagnosis, the survival benefit of BCT compared with mastectomy was uncertain, though some studies had been reported that BCT brought better body image and less anxiety for young breast cancer survivors (
Psychosocial factors have been reported to be associated with survival outcomes of cancer patients, and marital status is one of the most important psychosocial factors for breast cancer patients (
The present study aimed to investigate the impact of surgical approaches (mastectomy, BCT or PMBR) on the overall survival (OS) and breast cancer-specific survival (BCSS) for young patients with operable breast cancer in different marital statuses using the Surveillance, Epidemiology, and End Results (SEER) database.
We extracted data from the SEER database that was released in April 2019; specifically, the dataset named “Incidence-SEER 18 Res Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Sub (1975–2016 varying)” in the Case Listing and Frequency Sessions was obtained from the SEER*Stat software, version 8.3.6. The SEER database, including 18 tumor registries and representing approximately 28% of the population across the United States, contained information about patients’ demographics, characteristics of tumor, surgery type, hormone receptor status (HRs), survival months and vital status (
Flow diagram for creation of the study cohort. SEER, Surveillance, Epidemiology, and End Results; AJCC, American Joint Committee on Cancer; BCT, breast-conserving therapy; PMBR, post-mastectomy breast reconstruction.
The patients’ baseline characteristics among mastectomy, BCT and PMBR group were compared using Pearson’s chi-square test. Survival outcomes, including OS and BCSS, were examined using the Kaplan–Meier method and compared among the three surgical groups using Log-rank tests. Meanwhile, the survival outcomes among the three surgical groups were further analyzed in subgroups stratified by marital status. Hazard ratios (HR) with 95% confidence intervals (CIs) to assess the survival difference among different surgical groups were calculated using multivariate Cox proportional hazard regression. A two-sided P value <0.05 was considered to indicate statistical significance. All analyses in our study were performed using Statistical Product and Service Solutions (SPSS) software (version 26.0).
Some 20,885 young women with primary operable breast cancer were included in our study, among which 7,418 (35.5%) underwent mastectomy, 5,966 (28.6%) underwent BCT and 7,501 (35.9%) underwent PMBR. The median follow-up time was 66 months. The patients’ characteristics including demographics, age of diagnosis, characteristics of tumor, surgery approach, radiation, and chemotherapy are showed in
Comparison of baseline characteristics of operable breast cancer among various surgical groups.
Characteristics | Total (%) | MAS (%) | BCT (%) | PMBR (%) | p value |
---|---|---|---|---|---|
Overall | 20,885 | 7,418 | 5,966 | 7,501 | |
Age (years) | <0.001 | ||||
18–29 | 2,174 (10.4) | 785 (10.6) | 516 (8.6) | 873 (11.6) | |
30–39 | 18,711 (89.6) | 7,418 (89.4) | 5,450 (91.4) | 6,628 (88.4) | |
Marital status | <0.001 | ||||
Married | 13,402 (64.2) | 4,761 (64.2) | 3,607 (60.5) | 5,034 (67.1) | |
Unmarried | 7,483 (35.8) | 2,657 (35.8) | 2,359 (39.5) | 2,467 (32.9) | |
Race | <0.001 | ||||
White | 15,272 (73.1) | 5,316 (71.7) | 4,169 (69.9) | 5,787 (77.1) | |
Black | 2,941 (14.1) | 1,068 (14.4) | 959 (16.1) | 914 (12.2) | |
Others | 2,672 (12.8) | 1,034 (13.9) | 838 (14.0) | 800 (10.7) | |
Year of Diagnosis | <0.001 | ||||
2004–2009 | 8,971 (43.0) | 3,684 (49.7) | 3,098 (51.9) | 2,189 (29.2) | |
2010–2016 | 11,914 (57.0) | 3,734 (50.3) | 2,868 (48.1) | 5,312 (70.8) | |
Grade | <0.001 | ||||
Well differentiated | 1,560 (7.5) | 464 (6.3) | 564 (9.5) | 532 (7.1) | |
Moderately differentiated | 7,245 (34.7) | 2,410 (32.5) | 2,001 (33.5) | 2,834 (37.8) | |
Poorly differentiated | 11,886 (56.9) | 4,450 (60.0) | 3,346 (56.1) | 4,090 (54.5) | |
Undifferentiated/Anaplastic | 194 (0.9) | 94 (1.3) | 55 (0.9) | 45 (0.6) | |
AJCC stage | <0.001 | ||||
I | 6,115 (29.3) | 1,398 (18.8) | 2,302 (38.6) | 2,415 (32.2) | |
II | 10,426 (49.9) | 3,673 (49.5) | 3,068 (51.4) | 3,685 (49.1) | |
III | 4,344 (20.8) | 2,347 (31.6) | 596 (10.0) | 1,401 (18.7) | |
Tumor size | <0.001 | ||||
≤2 cm | 8,822 (42.2) | 2,390 (32.2) | 3,089 (51.8) | 3,343 (44.6) | |
>2 cm,≤5 cm | 9,456 (45.3) | 3,614 (48.7) | 2,631 (44.1) | 3,211 (42.8) | |
>5 cm | 2,519 (12.1) | 1,374 (18.5) | 239 (4.0) | 906 (12.1) | |
Unknown | 88 (0.4) | 40 (0.5) | 7 (0.1) | 41 (0.5) | |
LN status | <0.001 | ||||
Negative | 10,799 (51.7) | 2,968 (40.0) | 3,779 (63.3) | 4,052 (54.0) | |
Positive | 9,773 (46.8) | 4,339 (58.5) | 2,099 (35.2) | 3,335 (44.5) | |
No examined/Unknown | 313 (1.5) | 111 (1.5) | 88 (1.5) | 114 (1.5) | |
HRs | <0.001 | ||||
ER+/PR+ | 12,362 (59.2) | 4,141 (55.8) | 3,592 (60.2) | 4,629 (61.7) | |
ER+/PR− | 2,162 (10.4) | 811 (10.9) | 500 (8.4) | 851 (11.3) | |
ER−/PR+ | 407 (1.9) | 150 (2.0) | 112 (1.9) | 145 (1.9) | |
ER−/PR− | 5,954 (28.5) | 2,316 (31.2) | 1,762 (29.5) | 1,876 (25.0) | |
Radiation | <0.001 | ||||
No | 9,210 (44.1) | 4,197 (56.6) | 0 (0.0) | 5,013 (66.8) | |
Yes | 11,675 (55.9) | 3,221 (43.4) | 5,966 (100.0) | 2,488 (33.2) | |
Chemotherapy | <0.001 | ||||
No/Unknown | 3,771 (18.1) | 1,158 (15.6) | 1,119 (18.8) | 1,494 (19.9) | |
Yes | 17,114 (81.9) | 6,260 (84.4) | 4,847 (81.2) | 6,007 (80.1) |
MAS, mastectomy; BCT, breast-conserving therapy; PMBR, post-mastectomy breast reconstruction; AJCC, American Joint Committee on Cancer; LN, lymph node; HRs, hormone receptor status; ER, estrogen receptor; PR, progesterone receptor.
Kaplan–Meier curves were generated by surgical approach to estimate OS and BCSS of patients with operable breast cancer. In log‐rank tests, the BCT and PMBR group showed significantly (P <0.001) better OS and BCSS than mastectomy group, while less significant difference of OS and BCSS was observed between the BCT and PMBR group (
Kaplan–Meier survival curves: OS
Kaplan–Meier survival curves: OS
To further investigate the prognostic effect of surgery on survival by different demographic and pathological subgroups, we also stratified all cases according to age, race, AJCC stage, HRs, and whether receiving chemotherapy or not and conducted multivariate analyses (
Effects of surgery in overall survival by demographic and pathological subgroups.
OS | BCT |
PMBR |
PMBR |
|||
---|---|---|---|---|---|---|
Variable | AHR* (95%CI) | p value | AHR* (95%CI) | p value | AHR* (95%CI) | p value |
Age (years) | ||||||
18–29 | 0.66 (0.46–0.95) | 0.024 | 0.67 (0.50–0.90) | 0.008 | 0.90 (0.56–1.43) | 0.650 |
30–39 | 0.81 (0.70–0.93) | 0.003 | 0.70 (0.63–0.79) | <0.001 | 1.07 (0.89–1.28) | 0.468 |
Race | ||||||
White | 0.85 (0.72–0.99) | 0.041 | 0.74 (0.65–0.83) | <0.001 | 1.02 (0.84–1.24) | 0.846 |
Black | 0.72 (0.54–0.94) | 0.017 | 0.62 (0.49–0.79) | <0.001 | 1.12 (0.76–1.64) | 0.561 |
Others | 0.64 (0.43–0.96) | 0.029 | 0.62 (0.42–0.92) | 0.017 | 1.04 (0.58–1.85) | 0.906 |
AJCC stage | ||||||
I | 0.37 (0.21–0.65) | 0.001 | 0.59 (0.41–0.84) | 0.003 | 2.24 (1.12–4.47) | 0.022 |
II | 0.75 (0.62–0.91) | 0.004 | 0.82 (0.70–0.96) | 0.013 | 1.22 (0.96–1.55) | 0.110 |
III | 0.84 (0.69–1.02) | 0.070 | 0.65 (0.56–0.76) | <0.001 | 0.85 (0.67–1.08) | 0.187 |
HRs | ||||||
ER+/PR+ | 0.73 (0.60–0.89) | 0.002 | 0.73 (0.62–0.86) | <0.001 | 1.09 (0.85–1.41) | 0.497 |
ER+/PR− | 0.75 (0.48–1.16) | 0.197 | 0.85 (0.63–1.14) | 0.273 | 1.45 (0.87–2.40) | 0.151 |
ER−/PR+ | 0.74 (0.34–1.61) | 0.440 | 0.27 (0.13–0.56) | <0.001 | 0.46 (0.14–1.57) | 0.216 |
ER−/PR− | 0.85 (0.70–1.03) | 0.098 | 0.68 (0.58–0.81) | <0.001 | 0.92 (0.71–1.19) | 0.505 |
Chemotherapy | ||||||
No/Unknown | 0.97 (0.48–1.96) | 0.931 | 0.74 (0.51–1.07) | 0.106 | 1.74 (0.66–4.55) | 0.260 |
Yes | 0.78 (0.69–0.89) | <0.001 | 0.70 (0.63–0.79) | <0.001 | 1.02 (0.86–1.21) | 0.816 |
*With adjustment for race, age, marital status, T stage, N stage, histological grade, hormone receptor status, tumor size, surgery, radiation and chemotherapy.
OS, overall survival; AHR, adjusted hazard ratios; CI, confidential interval; MAS, mastectomy; BCT, breast-conserving therapy; PMBR, post-mastectomy breast reconstruction; HRs, hormone receptor status; ER, estrogen receptor; PR, progesterone receptor.
Effects of surgery in breast cancer-specific survival by demographic and pathological subgroups.
BCSS | BCT |
PMBR |
PMBR |
|||
---|---|---|---|---|---|---|
Variable | AHR* (95%CI) | p value | AHR* (95%CI) | p value | AHR* (95%CI) | p value |
Age (years) | ||||||
18–29 | 0.68 (0.47–0.98) | 0.038 | 0.71 (0.53–0.96) | 0.026 | 0.94 (0.58–1.52) | 0.804 |
30–39 | 0.81 (0.70–0.94) | 0.004 | 0.73 (0.65–0.82) | <0.001 | 1.09 (0.91–1.31) | 0.356 |
Race | ||||||
White | 0.86 (0.73–1.01) | 0.074 | 0.76 (0.67–0.86) | <0.001 | 1.01 (0.83–1.24) | 0.892 |
Black | 0.69 (0.52–0.92) | 0.011 | 0.64 (0.49–0.82) | <0.001 | 1.33 (0.91–1.96) | 0.142 |
Others | 0.65 (0.43–0.98) | 0.040 | 0.68 (0.46–1.01) | 0.053 | 1.15 (0.64–2.07) | 0.640 |
AJCC stage | ||||||
I | 0.34 (0.19–0.62) | <0.001 | 0.61 (0.42–0.88) | 0.009 | 2.51 (1.24–5.05) | 0.010 |
II | 0.75 (0.62–0.92) | 0.006 | 0.87 (0.74–1.03) | 0.095 | 1.24 (0.97–1.59) | 0.088 |
III | 0.83 (0.68–1.01) | 0.065 | 0.66 (0.56–0.77) | <0.001 | 0.87 (0.68–1.11) | 0.257 |
HRs | ||||||
ER+/PR+ | 0.76 (0.62–0.93) | 0.008 | 0.76 (0.64–0.89) | 0.001 | 1.08 (0.83–1.40) | 0.563 |
ER+/PR− | 0.81 (0.51–1.27) | 0.352 | 0.88 (0.65–1.19) | 0.399 | 1.49 (0.89–2.49) | 0.127 |
ER−/PR+ | 0.80 (0.35–1.79) | 0.578 | 0.30 (0.15–0.62) | 0.001 | 0.48 (0.14–1.69) | 0.255 |
ER−/PR− | 0.81 (0.67–0.99) | 0.043 | 0.71 (0.60–0.84) | <0.001 | 0.96 (0.74–1.25) | 0.784 |
Chemotherapy | ||||||
No/Unknown | 0.82 (0.39–1.74) | 0.604 | 0.73 (0.50–1.07) | 0.108 | 2.04 (0.70–5.90) | 0.189 |
Yes | 0.79 (0.69–0.91) | 0.001 | 0.73 (0.65–0.82) | <0.001 | 1.04 (0.88–1.24) | 0.659 |
*With adjustment for race, age, marital status, T stage, N stage, histological grade, hormone receptor status, tumor size, surgery, radiation and chemotherapy.
OS, overall survival; AHR, adjusted hazard ratios; CI, confidential interval; MAS, mastectomy; BCT, breast-conserving therapy; PMBR, post-mastectomy breast reconstruction; HRs, hormone receptor status; ER, estrogen receptor; PR, progesterone receptor.
Univariate analysis and adjusted multivariate analysis showed that unmarried status, black people, higher tumor grade (poorly differentiated or undifferentiated), lager tumor size (>2 cm), AJCC stage III and positive lymph node were independent risk factors for OS and BCSS, while receiving BCT or PMBR was protective factor for OS and BCSS (
Univariate and multivariate analysis of OS and BCSS for young women with operable breast cancer diagnosed between 2004 and 2016.
Characteristics | OS | BCSS | ||||||
---|---|---|---|---|---|---|---|---|
Univariate Analysis | Multivariate Analysis* | Univariate Analysis | Multivariate Analysis* | |||||
HR† (95%CI) | p value | HR† (95%CI) | p value | HR† (95%CI) | p value | HR† (95%CI) | p value | |
Age (years) | ||||||||
18–29 | Reference | – | Reference | – | Reference | – | Reference | – |
30–39 | 0.78 (0.72–0.85) | <0.001 | 0.89 (0.78–1.01) | 0.081 | 0.78 (0.71–0.85) | <0.001 | 0.89 (0.78–1.02) | 0.081 |
Marital status | ||||||||
Married | Reference | – | Reference | – | Reference | – | Reference | – |
Unmarried | 1.30 (1.19–1.41) | <0.001 | 1.22 (1.12–1.34) | <0.001 | 1.27 (1.17–1.39) | <0.001 | 1.20 (1.10–1.32) | <0.001 |
Race | ||||||||
White | Reference | – | Reference | – | Reference | – | Reference | – |
Black | 1.67 (1.50–1.85) | <0.001 | 1.33 (1.19–1.49) | <0.001 | 1.63 (1.46–1.82) | <0.001 | 1.31 (1.17–1.47) | <0.001 |
Others | 0.85 (0.73–0.98) | 0.021 | 0.89 (0.77–1.02) | 0.100 | 0.84 (0.73–0.98) | 0.022 | 0.89 (0.76–1.03) | 0.106 |
Year of Diagnosis | ||||||||
2004–2009 | Reference | – | Reference | – | Reference | – | Reference | – |
2010–2016 | 0.97 (0.88–1.07) | 0.549 | 1.06 (0.96–1.17) | 0.256 | 0.96 (0.87–1.06) | 0.426 | 1.05 (0.95–1.16) | 0.379 |
Grade | ||||||||
Well differentiated | Reference | – | Reference | – | Reference | – | Reference | – |
Moderately differentiated | 2.87 (2.09–3.95) | <0.001 | 1.93 (1.40–2.66) | <0.001 | 3.15 (2.24–4.44) | <0.001 | 2.09 (1.48–2.95) | <0.001 |
Poorly differentiated | 5.34 (3.91–7.28) | <0.001 | 2.59 (1.88–3.55) | <0.001 | 5.92 (4.24–8.28) | <0.001 | 2.81 (1.99–3.95) | <0.001 |
Undifferentiated/Anaplastic | 5.30 (3.40–8.26) | <0.001 | 2.55 (1.63–4.00) | <0.001 | 6.05 (3.80–9.63) | <0.001 | 2.85 (1.78–4.57) | <0.001 |
AJCC stage | ||||||||
I | Reference | – | Reference | – | Reference | – | Reference | – |
II | 2.81 (2.42–3.26) | <0.001 | 1.15 (0.93–1.42) | 0.193 | 2.96 (2.53–3.47) | <0.001 | 1.17 (0.94–1.46) | 0.153 |
III | 7.95 (6.85–9.23) | <0.001 | 2.23 (1.75–2.84) | <0.001 | 8.57 (7.33–10.03) | <0.001 | 2.33 (1.81–2.99) | <0.001 |
Tumor size | ||||||||
≤2 cm | Reference | – | Reference | – | Reference | – | Reference | – |
>2 cm,≤5 cm | 2.31 (2.08–2.57) | <0.001 | 1.40 (1.23–1.60) | <0.001 | 2.40 (2.16–2.68) | <0.001 | 1.43 (1.25–1.64) | <0.001 |
>5 cm | 4.81 (4.26–5.43) | <0.001 | 1.70 (1.45–2.00) | <0.001 | 4.95 (4.37–5.62) | <0.001 | 1.70 (1.44–2.00) | <0.001 |
LN status | ||||||||
Negative | 3.27 (2.97–3.61) | – | Reference | – | Reference | – | Reference | – |
Positive | 3.47 (2.59–4.65) | <0.001 | 2.08 (1.83–2.37) | <0.001 | 3.40 (3.07–3.76) | <0.001 | 2.12 (1.85–2.41) | <0.001 |
HRs‡ | ||||||||
ER+/PR+ | Reference | – | Reference | – | Reference | – | Reference | – |
ER+/PR− | 1.58 (1.37–1.82) | <0.001 | 1.31 (1.14–1.51) | <0.001 | 1.62 (1.40–1.87) | <0.001 | 1.34 (1.16–1.55) | <0.001 |
ER−/PR+ | 1.93 (1.49–2.50) | <0.001 | 1.98 (1.53–2.58) | <0.001 | 1.97 (1.51–2.57) | <0.001 | 2.02 (1.54–2.64) | <0.001 |
ER−/PR− | 2.06 (1.88–2.26) | <0.001 | 1.77 (1.60–1.95) | <0.001 | 2.10 (1.91–2.31) | <0.001 | 1.80 (1.62–1.99) | <0.001 |
Surgery | ||||||||
MAS | Reference | – | Reference | – | Reference | – | Reference | – |
BCT | 0.48 (0.44–0.54) | <0.001 | 0.76 (0.67–0.86) | <0.001 | 0.48 (0.43–0.54) | <0.001 | 0.76 (0.67–0.86) | <0.001 |
PMBR | 0.56 (0.50–0.62) | <0.001 | 0.71 (0.64–0.79) | <0.001 | 0.57 (0.51–0.63) | <0.001 | 0.73 (0.66–0.82) | <0.001 |
Radiation | ||||||||
No | Reference | – | Reference | – | Reference | – | Reference | – |
Yes | 1.30 (1.19–1.42) | <0.001 | 0.95 (0.85–1.05) | 0.287 | 1.33 (1.21–1.45) | <0.001 | 0.96 (0.86–1.07) | 0.465 |
Chemotherapy | ||||||||
No/Unknown | Reference | – | Reference | – | Reference | – | Reference | – |
Yes | 2.40 (2.06–2.79) | <0.001 | 1.18 (1.00–1.38) | 0.049 | 2.48 (2.12–2.91) | <0.001 | 1.18 (1.00–1.40) | 0.047 |
*With adjustment for age, race, marital status, year of diagnosis, AJCC stage, tumor size, lymph node status, histological grade, hormone receptor status, surgery, radiation and chemotherapy.
OS, overall survival; BCSS, breast cancer-specific survival; HR†, hazard ratios; CI, confidential interval; LN, lymph node; HRs‡, hormone receptor status; ER, estrogen receptor; PR, progesterone receptor; MAS, mastectomy; BCT, breast-conserving therapy; PMBR, post-mastectomy breast reconstruction.
By investigating the survival outcomes of young women with operable breast cancer treated with mastectomy, BCT or PMBR in a population of 20,885 patients from the SEER database, our study found that BCT or PMBR had improved OS and BCSS compared with mastectomy for young women with operable breast cancer, which remained significant in subgroup of unmarried patients. In subgroup of married patients, PMBR still conferred better OS and BCSS than mastectomy, but BCT did not. In addition, BCT and PMBR had equal OS and BCSS for young breast cancer patients, which were not affected by marital status.
Previous randomized controlled trials and large retrospective studies have demonstrated that BCT had better or at least equivalent survival outcomes compared with mastectomy (
In our finding, there was no significant difference in survival between BCT and PMBR, though PMBR usually brought more injuries to local tissues and needed more time to recover. This result might be attributable to the fact that both BCT and PMBR maintained patients’ body image to some extents and improved their psychosocial life, as the breast is a significant aspect of women’s body image and has an effect in how women are perceived by others or the society as well as in women’s self-perception (
To explore the differences of demographic and pathological factors between married and unmarried young patients, we found that unmarried patients had higher AJCC stage and larger tumor size, but had higher percentage of BCT (see
Unlike studies from single institution which had referral bias unavoidably, our study used SEER database, a large population-based cancer registry containing information from all levels of healthcare institutions, to present a more generalizable environment of clinical practice. There are several limitations in our study. Firstly, as a retrospective study including a large population from SEER database, there might existed data-entry errors and selection bias. Secondly, some information about marital status and prognosis of breast cancer patients could not be accessible in SEER database, including levels of hormone, reproductive history and subsequent treatments. Therefore, we could not further investigate the mechanism of the relationship between marital status and the prognosis of breast cancer patients; however, it might have little influence on the results of our research, which mainly focused on the impact of surgical approaches in survival outcomes for young women with operable breast cancer in different marital statuses. Thirdly, the information of ER and PR status was gathered from various pathology laboratories, possibly increasing bias of the data. Finally, information related to local recurrence and regional recurrence were unavailable in the SEER database, thus we failed to recognize patients with breast cancer recurrence who might have more advanced therapies.
By investigating the impact of surgical approaches in survival outcomes for young women with operable breast cancer in different marital statuses using the SEER database, our study demonstrated that both BCT and PMBR had improved survival compared with mastectomy for young women with operable breast cancer. The superiority of BCT in survival benefit to mastectomy was seen in unmarried patients but not in married patients. Meanwhile, BCT and PMBR had equal survival benefit for young breast cancer patients, which was not affected by marital status. According to our study, BCT should be recommended as the first option for young women with operable breast cancer whenever suitable; otherwise, PMBR is suggested to maintain the patients’ body image as much as possible.
Publicly available datasets were analyzed in this study. The data can be found at Surveillance, Epidemiology, and End Results (SEER) database (
This study was exempted by the ethics committee of Guangdong Provincial People's Hospital because our data were from the SEER database, which is de-identified and open to the public. And the SEER program approved the use of these data without the need for individual subject consent.
JZ, CY and YZ were involved in the design and coordination of the study as well as in data analysis, interpretation of results, and drafting the manuscript. KW was in charge of all study procedures. The others participated in the study procedures and critically revised the content of the manuscript. All authors contributed to the article and approved the submitted version.
This study is supported by grants from National Natural Science Foundation of China (Grant No. 81871513), Science and Technology Planning Project of Guangzhou City (202002030236), Science and Technology Special Fund of Guangdong Provincial People’s Hospital (No. Y012018218), CSCO-Hengrui Cancer Research Fund (Y-HR2016-067), Guangdong Provincial Department of Education Characteristic Innovation Project (2015KTSCX080), The Fundamental Research Funds for the Central Universities (2020ZYGXZR017) and Guangdong Basic and Applied Basic Research Foundation (2020A1515010346).
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors acknowledge the efforts of the Surveillance, Epidemiology, and End Results (SEER) program registries in the creation of the SEER database.
The Supplementary Material for this article can be found online at: